Freshpet, Inc. (FRPT) Stock Forecast
Data as of Jul 31, 2026Consumer Defensive · Current price $59.36 (-2.32%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 25, 2026 | Brian Holland | D.A. Davidson | $98.00 | +65.1% |
| Feb 24, 2026 | Thomas Palmer | Coker Palmer | $80.00 | +34.8% |
| Feb 24, 2026 | Eric Serotta | Morgan Stanley | $90.00 | +51.6% |
| Dec 15, 2025 | Steve Powers | Deutsche Bank | $62.00 | +4.4% |
| Nov 4, 2025 | Bryan Adams | UBS | $48.00 | -19.1% |
| Nov 4, 2025 | Brian Holland | D.A. Davidson | $83.00 | +39.8% |
| Nov 4, 2025 | Kaumil Gajrawala | Jefferies | $56.00 | -5.7% |
| Aug 7, 2025 | Brian Holland | D.A. Davidson | $101.00 | +70.1% |
| Jun 12, 2025 | Matthew Smith | Stifel Nicolaus | $90.00 | +51.6% |
| Apr 16, 2025 | Peter Benedict | Robert W. Baird | $125.00 | +110.6% |
| Mar 25, 2025 | Michael Lavery | Piper Sandler | $145.00 | +144.3% |
| Nov 5, 2024 | Mark Astrachan | Stifel Nicolaus | $165.00 | +178.0% |
| Nov 5, 2024 | Peter Benedict | Robert W. Baird | $170.00 | +186.4% |
| Nov 5, 2024 | Kaumil Gajrawala | Jefferies | $162.00 | +172.9% |
| Nov 5, 2024 | Brian Holland | D.A. Davidson | $189.00 | +218.4% |
| Oct 17, 2024 | Mark Astrachan | Stifel Nicolaus | $155.00 | +161.1% |
| Aug 6, 2024 | Ken Goldman | J.P. Morgan | $126.00 | +112.3% |
| Aug 6, 2024 | Peter Benedict | Robert W. Baird | $140.00 | +135.8% |
| Jul 2, 2024 | Michael Lavery | Piper Sandler | $150.00 | +152.7% |
| Jun 25, 2024 | Rupesh Parikh | Oppenheimer | $155.00 | +161.1% |
Top Analysts Covering FRPT
FRPT vs Sector & Market
| Metric | FRPT | Consumer Defensive Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.29 | 2.56 | 2.42 |
| Analyst Count | 24 | 10 | 19 |
| Target Upside | +34.1% | +1206.5% | +18.0% |
| P/E Ratio | 15.87 | 11.40 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.19B | $1.20B | $1.22B | 14 |
| 2027-03-31 | $313M | $318M | $324M | 5 |
| 2027-06-30 | $309M | $314M | $320M | 5 |
| 2027-09-30 | $332M | $337M | $343M | 5 |
| 2027-12-31 | $333M | $338M | $344M | 5 |
| 2028-03-31 | $339M | $345M | $351M | 4 |
| 2028-06-30 | $335M | $340M | $346M | 4 |
| 2028-09-30 | $358M | $364M | $370M | 4 |
| 2028-12-31 | $357M | $363M | $370M | 4 |
| 2029-12-31 | $1.50B | $1.53B | $1.56B | 3 |
| 2030-12-31 | $1.57B | $1.60B | $1.64B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.95 | $1.36 | $1.66 | 8 |
| 2027-03-31 | $0.26 | $0.27 | $0.28 | 2 |
| 2027-06-30 | $0.38 | $0.38 | $0.39 | 1 |
| 2027-09-30 | $0.55 | $0.56 | $0.58 | 1 |
| 2027-12-31 | $0.72 | $0.74 | $0.75 | 2 |
| 2028-03-31 | $0.58 | $0.60 | $0.61 | 3 |
| 2028-06-30 | $0.65 | $0.66 | $0.68 | 2 |
| 2028-09-30 | $0.82 | $0.84 | $0.86 | 2 |
| 2028-12-31 | $1.08 | $1.10 | $1.13 | 3 |
| 2029-12-31 | $2.43 | $2.50 | $2.58 | 1 |
| 2030-12-31 | $2.58 | $2.65 | $2.74 | 1 |
Frequently Asked Questions
What is the analyst consensus for FRPT?
The consensus among 24 analysts covering Freshpet, Inc. (FRPT) is Buy with an average price target of $77.33.
What is the highest price target for FRPT?
The highest price target for FRPT is $189.00, set by Brian Holland at D.A. Davidson on 2024-11-05.
What is the lowest price target for FRPT?
The lowest price target for FRPT is $48.00, set by Bryan Adams at UBS on 2025-11-04.
How many analysts cover FRPT?
24 analysts have issued ratings for Freshpet, Inc. in the past 12 months.
Is FRPT a buy or sell right now?
Based on 24 analyst ratings, FRPT has a consensus rating of Buy (2.29/5) with a +34.1% upside to the consensus target of $77.33.
What are the earnings estimates for FRPT?
Analysts estimate FRPT will report EPS of $1.36 for the period ending 2026-12-31, with revenue estimated at $1.20B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.